Digital health news briefs: Sophia Genetics acquires Biosoftware, Garmin improves sleep tracking, Yaoshibang gets $66M

Sophia Genetics acquires CDS software company. Genomics AI company Sophia Genetics has acquired Interactive Biosoftware, a maker of Alamut, a clinical decision support software for clinical genomic data interpretation. The terms of the deal were not disclosed.

Digital mental health platform Healios raises $2.9M

UK-based digital mental health company Healios has just closed a $2.9 million (£2.2 million) funding round led by Albion Capital and Spice Capital. 

The platform connects patients to mental health professionals for assessments, treatments, and wellbeing check-ins. It also gives patients and clinicians the ability to connect through video conferencing and interactive digital tools. The digital health tool is designed so that different family members can be connected on the platform. 

Care, wellness robotics company Embodied collects $22M

Pasadena, California-based Embodied announced today it has raised $22 million in Series A funding to support its AI and robotics platforms for improved care and wellness. The investment is led by Calibrate Ventures and Jazz Venture Partners, and had participation from previous backers including Osage University Partners, Intel Capital, Grishin Robotics, and others.

In-Depth: Consumer genomics furthers healthcare foothold but privacy, resource concerns persist

In the last few years consumer genomics has grown in both its offerings and legitimacy. The industry that was once best known for telling clients if they were Italian or Hungarian is now securing its foothold within the healthcare space. 

Benchling gets $14.5M to build collaboration tools for biotechs, pharmas

Benchling, which offers a software suite for improving collaboration and productivity among life sciences and biotech researchers, has raised $14.5 million in series B funding. Benchmark led the round, with additional participation by F-Prime Capital and returning investor Thrive Capital.

Valencell's partnership with earphone manufacturer leads to $10.5M raise

Biometric sensor technology company Valencell announced this week that it has raised $10.5 million in Series E, bringing the company’s total funding to $35 million. The new backing primarily comes as the result of a strategic investment by hearing instrument and specialty earphone company Sonion a/s, with additional participation from prior investors including TDF Ventures, GII LLC, and WSJ Joshua Fund.

Digital brain biomarker startup raises $15M in Series B funding

Mindstrong Health, a company that uses phone activity to measure mental health and behavior, has just closed a $15 million Series B funding round. 

This newest backing brings the startups total financing to $29 million, and will be used to scale the business and advance commercial deployments with partners in the healthcare industry. Mindstrong is backed by ARCH Venture Partners, Berggruen Holdings, Bezos Expeditions, Decheng Capital, Foresite Capital, Optum Ventures, and One Mind Brain Health Impact Fund.

FDA approves wearable device for opioid withdrawal symptom treatment device

DyAnsys, a medical device company specializing in the autonomic nervous system, announced this week that it has received FDA approval for a wearable auricular neurostimulation device designed to treat symptoms of opioid withdrawal.

The device, called Drug Relief, is now available to providers in the US, and is distributed in the EU by the DyAnsys’ European branch.